Mobile website
Clinical Research
Analysis of the relationship between checkpoint inhibitor-related pneumonitis and the efficacy of immune checkpoint inhibitor in patients with non-small cell lung cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate the relationship between the incidence of immune checkpoint inhibitor-associated pneumonia (CIP) and the efficacy of immunotherapy in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs), and to explore the prognostic factors of patients receiving ICI treatment. Methods: The clinical and follow-up data of 145 NSCLC patients treated with ICIs in the Affiliated Cancer Hospital of Xinjiang Medical University from March 2020 to March 2023 were retrospectively analyzed. The patients were divided into CIP group and non-CIP group. The patients with CIP were sub-divided into mild (grade 1, 2) and severe (grade 3, 4) CIP subgroups. The effects of the occurrence and severity of CIP on the overall survival (OS) time and progression-free survival (PFS) time of the patients were analyzed by comparing the survival curve using Kaplan-Meier method. Univariate and multivariate COX proportional hazard regression models were used to analyze the prognostic factors associated with PFS and OS. Results: A total of 26 patients developed CIP, with an incidence rate of 17.93% (26/145), and the incidence of severe CIP was 3.4%. The PFS in CIP group was significantly longer than that in non-CIP group (12.3 vs 7.6 months, P<0.05). There was no significant difference in OS between CIP group and non-CIP group (16.2 vs 15.8 months, P>0.05). Subgroup analysis showed that there were no significant differences in PFS (12.2 vs 12.9 months) and OS (16.1 vs 17.8 months) between mild CIP and severe CIP groups (all P>0.05). Multivariate COX regression analysis showed that CIP (HR=0.55, 95%CI [0.33,0.90], P=0.02) and the course of immunotherapy >6 cycles (HR=0.51, 95%CI [0.31, 0.85], P=0.01) were favorable prognostic factors for PFS. The course of immunotherapy >6 cycles (HR=0.4, 95%CI [0.18,0.88], P=0.02) was a favorable prognostic factor for OS. Conclusion: The incidence of CIP is 17.93%. The occurrence of CIP is closely related to the prolongation of PFS. Immunotherapy course >6 cycles is a favorable prognostic factor for PFS and OS of NSCLC patients.
Keywords:
Project Supported:
Clc Number:
